Grace Therapeutics grants 267K options to CEO

Grace Therapeutics, Inc. (GRCE) reported that Chief Executive Officer and director Prashant Kohli received a grant of 267,160 stock options on 2026-08-28.

Rhea-AI Filing Summary

Grace Therapeutics, Inc. (GRCE) reported that Chief Executive Officer and director Prashant Kohli received a grant of 267,160 stock options on 2026-08-28. The options have an exercise price of $2.12 per share, expire on 2036-08-27, and relate to 267,160 shares of common stock. According to the vesting terms, 1/12 of the options vested immediately on the grant date and the remaining 11/12 vest in substantially equal quarterly installments over the following 11 quarters, subject to his continuous service.

Insider Trade Summary

Grant/Award: 267,160 shares

Grant/Award 1 txn

Insider Kohli Prashant

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	267,160	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 267,160 contracts (Direct)

Footnotes (1)

1. F1. These options vest quarterly in substantially equal installments over a three-year period, subject to the Reporting Person's continuous service as of each vesting date, The first 1/12 tranche shall vest immediately upon the grant date with the remaining 11/12 vesting equally over the following 11 quarters starting on the three-month anniversary of the grant date.

Key Figures

Stock options granted: 267,160 options Exercise price: $2.12 per share Underlying common shares: 267,160 shares +3 more

6 metrics

Stock options granted 267,160 options Grant to CEO Prashant Kohli on 2026-08-28

Exercise price $2.12 per share Conversion or exercise price for the granted stock options

Underlying common shares 267,160 shares Shares of Grace Therapeutics common stock underlying the options

Expiration date 2036-08-27 Expiry of the granted stock options

Immediate vesting tranche 1/12 of options Vests immediately on the grant date, per footnote

Remaining vesting schedule 11 quarterly installments Remaining 11/12 of options vest over the following 11 quarters

Key Terms

Stock Option (Right to Buy), exercise price, vesting, grant date

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 2.1200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"These options vest quarterly in substantially equal installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

grant date financial

"vest immediately upon the grant date with the remaining 11/12"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GRCE report for Prashant Kohli?

Grace Therapeutics reported that CEO and director Prashant Kohli received a grant of 267,160 stock options on 2026-08-28, giving him the right to buy 267,160 shares of common stock at an exercise price of $2.12 per share until 2036-08-27.

What is the exercise price of the new stock options granted by GRCE to its CEO?

The stock options granted to Grace Therapeutics CEO Prashant Kohli have an exercise price of $2.12 per share, allowing the purchase of up to 267,160 shares of the company’s common stock, subject to vesting and expiration on 2036-08-27.

How do the newly granted GRCE stock options to the CEO vest?

The options granted to Grace Therapeutics CEO Prashant Kohli vest over three years: 1/12 vested immediately on the grant date, and the remaining 11/12 vest in substantially equal quarterly installments over the next 11 quarters, contingent on his continuous service.

When do Prashant Kohli’s newly granted GRCE stock options expire?

The stock options granted to Prashant Kohli by Grace Therapeutics expire on 2036-08-27. Until that date, once vested, they allow him to purchase up to 267,160 shares of GRCE common stock at an exercise price of $2.12 per share.

How many GRCE stock options does the CEO hold after this grant?

After this award, Grace Therapeutics CEO Prashant Kohli holds 267,160 stock options associated with this specific grant, as reported as the total derivative securities following the transaction in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 04:08 PM EDT Accepted by SEC EDGAR 09/01/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kohli Prashant

(Last) (First) (Middle)

C/O GRACE THERAPEUTICS, INC.

103 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Grace Therapeutics, Inc. [ GRCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.12	08/28/2026		A		267,160		(1)	08/27/2036	Common Stock	267,160	$0	267,160	D

Explanation of Responses:

1. These options vest quarterly in substantially equal installments over a three-year period, subject to the Reporting Person's continuous service as of each vesting date, The first 1/12 tranche shall vest immediately upon the grant date with the remaining 11/12 vesting equally over the following 11 quarters starting on the three-month anniversary of the grant date.

	/s/ Robert DelAversano as attorney-in-fact for Prashant Kohli	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)